Browsing by Subject "skin atrophy"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Parry-Romberg syndrome: A possible association with borreliosis
    (2004) Şahin M.T.; Bariş S.; Karaman A.
    Progressive facial hemiatrophy or Parry-Romberg syndrome is a rare entity characterized by unilateral atrophy of the skin, subcutaneous tissue and the underlying bony structures. This syndrome has many features of linear scleroderma 'en coup de sabre' but is distinguished by more extensive involvement of the lower face with only slight cutaneous sclerosis. The onset typically occurs in childhood or young adult years. The aetiology of the condition is unknown. A case of progressive hemifacial atrophy occurring in a 30-year-old woman is reported, in which the aetiology is thought to be Lyme disease, a borrelial infection first recognized in 1975 that has since become the most commonly reported vector-borne disease in the world. No sure link is established between these two disease states, but their coincident occurrence in this patient is noted. We hypothesize that the aetiology of Parry-Romberg syndrome involves borreliosis. © 2004 European Academy of Dermatology and Venereology.
  • No Thumbnail Available
    Item
    Inappropriate treatments at beauty centers: A case report of burns caused by hot wax stripping [2]
    (Japanese Dermatological Association, 2004) Türel-Ermertcan A.; Şahin M.T.; Yurtman D.; Kapulu N.; Öztürkcan S.
    [No abstract available]
  • No Thumbnail Available
    Item
    Topical calcineurin inhibitors, pimecrolimus and tacrolimus
    (2007) Ermertcan A.T.; Öztürkcan S.
    Pinecrolimus and tacrolimus represent the first members of a new class of medications, calcineurin inhibitors. These topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. They inhibit T cell proliferation, mast cell degranulation, production and release of IL-2, IL-4, IF-γ and TNF-αa. They do not effect endothelial cells and fibroblasts, so they do not induce skin atrophy. In several studies, it has been shown that topical pimecrolimus and tacrolimus are effective, well tolerated and safe in both adults and children with atopic dermatitis. Picmecrolimus permeates less through the skin than tacrolimus and much lessthan corticosteroids. It has a lower potential for transcutaneous absorption resulting in a lower risk of systemic effects. In addition, they have been used in other inflammatory skin diseases including psoriasis, lichen planus, seborrheic dermatitis, allergic contact dermatitis, vitiligo, pyoderma gangrenosum, alopecia areata, graft versus host disease, akne rosacea, etc. In this review article mechanism of action, efficacy, safety of pimecrolimus and tacrolimus, and future directions of these immunomodulators were discussed. © 2007 Bentham Science Publishers Ltd.